196 related articles for article (PubMed ID: 32838755)
21. Developmental delay with hypotrophy associated with homozygous functionally relevant REV3L variant.
Halas A; Fijak-Moskal J; Kuberska R; Murcia Pienkowski V; Kaniak-Golik A; Pollak A; Poznanski J; Rydzanicz M; Bik-Multanowski M; Sledziewska-Gojska E; Płoski R
J Mol Med (Berl); 2021 Mar; 99(3):415-423. PubMed ID: 33474647
[TBL] [Abstract][Full Text] [Related]
22. Mutations in POLE and survival of colorectal cancer patients--link to disease stage and treatment.
Stenzinger A; Pfarr N; Endris V; Penzel R; Jansen L; Wolf T; Herpel E; Warth A; Klauschen F; Kloor M; Roth W; Bläker H; Chang-Claude J; Brenner H; Hoffmeister M; Weichert W
Cancer Med; 2014 Dec; 3(6):1527-38. PubMed ID: 25124163
[TBL] [Abstract][Full Text] [Related]
23. The Polymerase Activity of Mammalian DNA Pol ζ Is Specifically Required for Cell and Embryonic Viability.
Lange SS; Tomida J; Boulware KS; Bhetawal S; Wood RD
PLoS Genet; 2016 Jan; 12(1):e1005759. PubMed ID: 26727495
[TBL] [Abstract][Full Text] [Related]
24. POLE/POLD1 mutation and tumor immunotherapy.
Ma X; Dong L; Liu X; Ou K; Yang L
J Exp Clin Cancer Res; 2022 Jul; 41(1):216. PubMed ID: 35780178
[TBL] [Abstract][Full Text] [Related]
25. Polymerase epsilon mutations and concomitant β2-microglobulin mutations in cancer.
Voutsadakis IA
Gene; 2018 Mar; 647():31-38. PubMed ID: 29320758
[TBL] [Abstract][Full Text] [Related]
26. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.
Stasenko M; Tunnage I; Ashley CW; Rubinstein MM; Latham AJ; Da Cruz Paula A; Mueller JJ; Leitao MM; Friedman CF; Makker V; Soslow RA; DeLair DF; Hyman DM; Zamarin D; Alektiar KM; Aghajanian CA; Abu-Rustum NR; Weigelt B; Cadoo KA
Gynecol Oncol; 2020 Jan; 156(1):194-202. PubMed ID: 31757464
[TBL] [Abstract][Full Text] [Related]
27. Mutational processes of distinct POLE exonuclease domain mutants drive an enrichment of a specific TP53 mutation in colorectal cancer.
Fang H; Barbour JA; Poulos RC; Katainen R; Aaltonen LA; Wong JWH
PLoS Genet; 2020 Feb; 16(2):e1008572. PubMed ID: 32012149
[TBL] [Abstract][Full Text] [Related]
28. Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma.
Hoang LN; McConechy MK; Köbel M; Anglesio M; Senz J; Maassen M; Kommoss S; Meng B; Postovit L; Kelemen LE; Staebler A; Brucker S; Krämer B; McAlpine JN; Gilks CB; Huntsman DG; Lee CH
Int J Gynecol Cancer; 2015 Sep; 25(7):1187-93. PubMed ID: 26166557
[TBL] [Abstract][Full Text] [Related]
29. DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden.
Riggs MJ; Lin N; Wang C; Piecoro DW; Miller RW; Hampton OA; Rao M; Ueland FR; Kolesar JM
PLoS One; 2020; 15(12):e0244558. PubMed ID: 33378353
[TBL] [Abstract][Full Text] [Related]
30. High mutational burden in colorectal carcinomas with monoallelic POLE mutations: absence of allelic loss and gene promoter methylation.
Hühns M; Nürnberg S; Kandashwamy KK; Maletzki C; Bauer P; Prall F
Mod Pathol; 2020 Jun; 33(6):1220-1231. PubMed ID: 31857678
[TBL] [Abstract][Full Text] [Related]
31. The hereditary N363K POLE exonuclease mutant extends PPAP tumor spectrum to glioblastomas by causing DNA damage and aneuploidy in addition to increased mismatch mutagenicity.
Labrousse G; Vande Perre P; Parra G; Jaffrelot M; Leroy L; Chibon F; Escudie F; Selves J; Hoffmann JS; Guimbaud R; Lutzmann M
NAR Cancer; 2023 Jun; 5(2):zcad011. PubMed ID: 36915289
[TBL] [Abstract][Full Text] [Related]
32. Characterization of POLE c.1373A > T p.(Tyr458Phe), causing high cancer risk.
Rocque MJ; Leipart V; Kumar Singh A; Mur P; Olsen MF; Engebretsen LF; Martin-Ramos E; Aligué R; Sætrom P; Valle L; Drabløs F; Otterlei M; Sjursen W
Mol Genet Genomics; 2023 May; 298(3):555-566. PubMed ID: 36856825
[TBL] [Abstract][Full Text] [Related]
33. Concurrent genetic alterations in DNA polymerase proofreading and mismatch repair in human colorectal cancer.
Yoshida R; Miyashita K; Inoue M; Shimamoto A; Yan Z; Egashira A; Oki E; Kakeji Y; Oda S; Maehara Y
Eur J Hum Genet; 2011 Mar; 19(3):320-5. PubMed ID: 21157497
[TBL] [Abstract][Full Text] [Related]
34. The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis.
Jumaah AS; Al-Haddad HS; McAllister KA; Yasseen AA
PLoS One; 2022; 17(2):e0263585. PubMed ID: 35139130
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant Treatment for
Van Gool IC; Rayner E; Osse EM; Nout RA; Creutzberg CL; Tomlinson IPM; Church DN; Smit VTHBM; de Wind N; Bosse T; Drost M
Clin Cancer Res; 2018 Jul; 24(13):3197-3203. PubMed ID: 29559562
[No Abstract] [Full Text] [Related]
36. Replication DNA polymerases, genome instability and cancer therapies.
Strauss JD; Pursell ZF
NAR Cancer; 2023 Sep; 5(3):zcad033. PubMed ID: 37388540
[TBL] [Abstract][Full Text] [Related]
37. Validation of computational determination of microsatellite status using whole exome sequencing data from colorectal cancer patients.
Johansen AFB; Kassentoft CG; Knudsen M; Laursen MB; Madsen AH; Iversen LH; Sunesen KG; Rasmussen MH; Andersen CL
BMC Cancer; 2019 Oct; 19(1):971. PubMed ID: 31638937
[TBL] [Abstract][Full Text] [Related]
38. POLE gene hotspot mutations in advanced pancreatic cancer.
Guenther M; Veninga V; Kumbrink J; Haas M; Westphalen CB; Kruger S; Heinemann V; Kirchner T; Boeck S; Jung A; Ormanns S
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2161-2166. PubMed ID: 30194485
[TBL] [Abstract][Full Text] [Related]
39. Human Pol ε-dependent replication errors and the influence of mismatch repair on their correction.
Agbor AA; Göksenin AY; LeCompte KG; Hans SH; Pursell ZF
DNA Repair (Amst); 2013 Nov; 12(11):954-63. PubMed ID: 24051051
[TBL] [Abstract][Full Text] [Related]
40. Chimeric thermostable DNA polymerases with reverse transcriptase and attenuated 3'-5' exonuclease activity.
Schönbrunner NJ; Fiss EH; Budker O; Stoffel S; Sigua CL; Gelfand DH; Myers TW
Biochemistry; 2006 Oct; 45(42):12786-95. PubMed ID: 17042497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
